Biocept Saham

Biocept EBITDA

Delisted

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari Biocept (BIOC) pada 4 Agu 2026 adalah -31,98 Juta. USD. Tahun sebelumnya, EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) adalah -2,41 Juta. USD — perubahan sebesar 1.227,65% (lebih rendah).

EBITDA

-31,98 Juta.USD

YoY

1.227,65%

Terakhir Diperbarui:

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari Biocept adalah 2026 -31,98 Juta. USD. EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari Biocept adalah 2025 -2,41 Juta. USD. Menurun 1.227,65% lebih rendah dibandingkan dengan tahun sebelumnya.
Access this data via the Eulerpool API

Biocept Analisis saham

Apa yang dilakukan Biocept? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept adalah salah satu perusahaan paling populer di Eulerpool.

Pertanyaan yang Sering Diajukan tentang saham Biocept

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) Biocept adalah -31,98 Juta. USD pada tahun 2026.

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari Biocept berubah dari -2,41 Juta. USD menjadi -31,98 Juta. USD, mewakili perubahan 1.227,65%. Nilainya lebih rendah daripada tahun sebelumnya.

Di Eulerpool Anda dapat menemukan perkembangan historis lengkap EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) Biocept sejak 2006 – dengan nilai tahunan, bagan, dan analisis detail.

EBITDA mengukur kinerja operasional sebelum dampak struktur keuangan, lingkungan pajak, dan biaya penyusutan non-kas.

EBITDA = EBIT + Penyusutan & Amortisasi

USD EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) adalah faktor kunci bagi investor. Perubahan metrik ini dapat menunjukkan fundamental yang membaik atau memburuk, secara langsung memengaruhi harga saham. Di Eulerpool, Anda dapat melacak Biocept EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) secara historis dan real-time.

Access this data via the Eulerpool API

Laporan Laba Rugi — Biocept

Semua Metrik Kunci — Biocept